Network Pharmacology Integrated Experimental Validation Uncover Quercetin as the Key Ingredient of Hedyotis diffusa Anti‐ BRCA
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70112 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2025. Written by Queting Chen and 7 co-authors. Institution: Department of Breast Surgery, Affiliated Hospital of Hebei University, Baoding, China. Major MEDLINE topics: Breast Neoplasms, Quercetin, Hedyotis, Antineoplastic Agents, Phytogenic. Cited 2 times so far (Crossref); 46 references. Funded by: the Innovation Capacity Improvement Plan of Hebei Province, Natural Science Foundation of Hebei Province, China, Foundation of Affiliated Hospital of Hebei University.
Abstract (original language)
Hedyotis diffusa , a famous Traditional Chinese Medicine (TCM), has been extensively used clinically for thousands of years. Although the therapeutic effect of Hedyotis diffusa on tumors has attracted wide attention, components, and mechanisms against breast cancer (BRCA) have not been fully understood. The study aims to explore the active components and molecular mechanisms of Hedyotis diffusa against BRCA using network pharmacology combined with experimental validation. The results of network pharmacology indicated that quercetin was the most core component of Hedyotis diffusa . BIRC5, CDK1, FOS, and HSP90AA1 were considered candidate key targets of Hedyotis diffusa against BRCA. KEGG enrichment analysis revealed that multiple cancer‐related pathways are enriched, including pathways in cancer, estrogen signaling pathway, and PI3K‐AKT signaling pathway, and the like. The results of in vitro experiments showed that quercetin inhibited the proliferation of both MCF‐7 cells and MDA‐MB‐231 cells in a dose‐dependent manner. Furthermore, the experimental data demonstrated quercetin may decrease the expression level of BIRC5, CDK1, and HSP90AA1 in MCF‐7 cells. Overall, results of the study indicated that quercetin may play a vital role in the anti‐BRCA effect of Hedyotis diffusa , and quercetin can affect the expression of BIRC5, CDK1, and HSP90AA1 in MCF‐7 cells. This study may provide new evidence for the use of Hedyotis diffusa in the treatment of BRCA.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Breast Surgery, Affiliated Hospital of Hebei University, Baoding, China.
- College of Life Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Hebei University, Baoding, China.
- School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China.
- College of Pharmaceutical Science, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, State Key Laboratory of new Pharmaceutical Preparations and Excipients, Key Laboratory of Medicinal Chemistry and Mo…
ORCID profiles: Zhiqin Liu
Funding
- the Innovation Capacity Improvement Plan of Hebei Province
- Natural Science Foundation of Hebei Province, China
- Foundation of Affiliated Hospital of Hebei University
- the Medical Science Foundation of Hebei University
- the Science and technology support plan of Baoding City
- National Natural Science Foundation of China
- Natural Science Foundation of Hebei Province
Cite
APA
Chen, Q., Xu, Y., Ma, J., Zhang, G., Yin, Z., Zhang, D., Luo, D., & Liu, Z. (2025). Network Pharmacology Integrated Experimental Validation Uncover Quercetin as the Key Ingredient of Hedyotis diffusa Anti‐ BRCA. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70112
Vancouver
Chen Q, Xu Y, Ma J, Zhang G, Yin Z, Zhang D, et al. Network Pharmacology Integrated Experimental Validation Uncover Quercetin as the Key Ingredient of Hedyotis diffusa Anti‐ BRCA. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70112
BibTeX
@article{Chen2025,
author = {Chen, Queting and Xu, Yuanzhuang and Ma, Jianhua and Zhang, Gaotao and Yin, Zhengyu and Zhang, Donghao and Luo, Duqiang and Liu, Zhiqin},
title = {Network Pharmacology Integrated Experimental Validation Uncover Quercetin as the Key Ingredient of Hedyotis diffusa Anti‐ BRCA},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70112}
}
EUVIMED